Atherosclerosis is associated with system inflammation markers of interstitial lung disease (ILD) and pulmonary fibrosis (ILD-PF), including interleukin (IL)-6, IL-17, and the anti-inflammatory IL-10, as well as angiotensin-converting enzyme 2 (ACE2) [1–6]. Here, IL17A is linked to pulmonary fibrosis.